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Abstract: Ropinirole is a dopamine agonist, approved for use to treat symptoms of early and 
advanced Parkinson’s disease, is now available in a 24-hour formulation in addition to the immediate 
release version. This review discusses the mode of action of ropinirole and compares the pharmacoki-
netics of both formulations. Pivotal studies leading to the approval of both preparations are reviewed 
in terms of efﬁ  cacy, dose range and side effects. Patient factors such as compliance are discussed 
in terms of the place for ropinirole in the armamentarium of Parkinson’s disease therapies.
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Introduction
For over a decade, ropinirole has been available for use in the management of early 
and advanced Parkinson’s disease (PD). More recently, ropinirole extended release 
(Requip® XL™) has been approved for management of PD. We review the basic phar-
macology of both forms of ropinirole and discuss the place of ropinirole extended 
release (24-hour) in the various stages of treatment of Parkinson’s disease.
Overview of pharmacology
Mode of action
Ropinirole is a non-ergoline dopamine agonist with preferential afﬁ  nity for the D2-like 
(D2, 3, 4) receptors.1 It has highest afﬁ  nity at the D3 receptors which are concentrated 
in the limbic areas of the brain and may account for some of the neuropsychiatric 
effects. Lesser, but still signiﬁ  cant, afﬁ  nity is seen at the D2 receptor in the striatum 
accounting for the prominent beneﬁ  ts on the motor symptoms of PD. Negligible afﬁ  nity 
is seen at α2 adrenoreceptors in the periphery and 5HT-1 receptor. Ropinirole has no 
afﬁ  nity at the D1-like receptors, benzopdiazepine or GABA receptors.
The α2 adrenoceptor afﬁ  nity may account for the cardiovascular effects seen with 
ropinirole as this effect can be blocked by the peripherally active agent domperidone.2,3 
Tolerance to the cardiovascular effect is recognized, occurring after approximately 
one week of treatment.4
Ropinirole also has binding to lactotrophs in the anterior pituitary;5 however, the 
signiﬁ  cance of this in the management of PD is likely minimal.
Putative neuroprotective effects in PD have been postulated given that ropinirole 
may have antioxidant effects in vivo;6 however, clinical studies report conﬂ  icting 
results,7,8 and the matter is still debated.
Pharmacokinetics
Ropinirole immediate release
After oral administration, ropinirole is rapidly absorbed with a typical Cmax of 
1–2 hours.9,10 Oral bioavailability is approximately 50%. Volume of distribution is Neuropsychiatric Disease and Treatment 2009:5 34
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large at approximately 7.5 L/kg. Plasma protein binding 
is approximately 40%.11 Ropinirole is metabolized by the 
CYP-1A2 system. However, theophylline (CYP-1A2 inhibitor) 
administration showed no signiﬁ  cant drug-drug interactions.12 
Ciproﬂ  oxacin, another inhibitor of CYP-1A2, produced an 
increase in ropinirole Cmax by 60% without signiﬁ  cant change 
in the clinical status of patients with PD.13 Hormone replace-
ment therapy reduced clearance by 33% and advanced age had 
a small effect on reducing clearance.13 Taking ropinirole with 
food delays the time to Cmax by 2.6 hours but has no effect on the 
extent of absorption. 14 Logically, dopamine antagonists such as 
typical dopamine receptor blocking drugs (eg, phenothiazines 
or metoclopramide) may reduce the efﬁ  cacy of ropinirole.
Most of absorbed dose of ropinirole is cleared by the 
liver with only 10% being excreted unchanged in the urine.15 
There are two metabolites, neither of which are pharmaco-
logically active. Terminal half-life of ropinirole is about 
6 hours (although there is a range of 2–10 hours) and is 
independent of dose.16
Ropinirole immediate release exhibits linear pharmacoki-
netics and given its proﬁ  le, is typically administered as a three 
times a day medication. At steady state, the Cmax is roughly 
double what is seen in single dosing studies. The average 
peak to trough ratio is approximately 2:1.16
Ropinirole 24-hour
Ropinirole 24-hour is designed as a once daily long-acting 
formulation and comes in strengths that allow easy titration and 
switch from the immediate release formulation. In a comparison 
study17 with immediate release given every 8 hours, the 24-hour 
ropinirole had a Tmax occurring 6 hours after administration, com-
pared with 2 hours for the immediate release. After attainment 
of the Cmax, the level slowly declined over the 24-hour period 
to a trough level roughly equivalent to the troughs seen with 
three times daily dosing of the immediate release. Dose normal-
ized total concentration (AUCs) were approximately the same, 
whereas Cmax was about 12% lower with ropinirole 24-hour. 
No signiﬁ  cant food effects were seen. In clinical practice, if 
immediate release ropinirole is given with meals, the 12-hour 
gap between last evening dose and breakfast dosing, the differ-
ences between peak and trough levels may be as much as 5-fold, 
compared with the 2-fold change seen with ropinirole 24-hour. 
Whether that is clinically relevant, remains uncertain.
Efﬁ  cacy
Ropinirole immediate release
Ropinirole immediate release has a long established position 
in the management of Parkinson’s disease. Short duration 
studies in early Parkinson’s disease demonstrated a superior 
response to placebo for ropinirole monotherapy.18,19 Average 
total daily doses for these studies were 15.7 mg/day and 
6.54 mg/day respectively. A 3-year study comparing ropini-
role to bromocriptine (an ergoline dopamine agonist) showed 
a similar efﬁ  cacy, safety and tolerability.20 A 5-year study 
of 268 subjects compared ropinirole to levodopa directly.7 
The study monitored motor function as well as dopaminergic 
side effects. Ropinirole reduced the incidence of dyskinesia 
(45% versus 20%) as a primary motor complication of 
levodopa, as well as reduced the need for supplemental 
levodopa (total levodopa doses of 427 mg versus 753 mg). 
Of the original 179 subjects who originally were assigned 
to receive ropinirole, 29 (16%) remained in the study at 
5 years on monotherapy. Although subjects experienced 
fewer dopaminergic motor complications in the ropinirole 
group, this was at the price of reduced efﬁ  cacy in terms of 
both the motor examination and activities of daily living. 
The magnitude of the difference as measured by the UPDRS 
was 1.53 points for activities of daily living (p = 0.08) and 
4.48 for motor examination (p = 0.008). It is important to 
recognize the limitation of this type of study, as only about 
50% of subjects completed the study (regardless of arm) and 
the study constrained the use of supplemental medication to 
levodopa only which does not reﬂ  ect current practice. This 
study also had a neuroimaging arm where a subset of subjects 
received  18F-dopa positron emission tomography as an 
indirect marker of dopamine neuron loss.8 The 2-year study 
demonstrated that those originally assigned to ropinirole 
(n = 68) had a 14.1% decrease if ﬂ  uorodopa uptake in the 
putamen compared with 22.9% decrease in those originally 
on levodopa (n = 59). Since this ﬁ  nding is in conﬂ  ict with the 
ﬁ  ndings of reduced clinical efﬁ  cacy, there has been skepti-
cism of whether this ﬁ  ndings represents neuroprotection or 
may be explained by a pharmacological difference in the 
two drugs with respect to ﬂ  uorodopa uptake. Most recently, 
10-year follow-up data have been published demonstrating 
continued clinical beneﬁ  t to ropinirole in a more naturalistic 
setting.21
Ropinirole has also been studied in more advanced PD. 
A placebo controlled study in patient not adequately con-
trolled with levodopa showed a signiﬁ  cant improvement in 
off time (35% versus 13%) and in daily levodopa reduction 
(242 mg versus 51 mg).22 A 16-week comparison study with 
bromocriptine showed that ropinirole added to levodopa 
therapy reduced the need for levodopa and had similar reduc-
tion in off time and improvement in the motor portion of the 
UPDRS compared to bromocriptine.23Neuropsychiatric Disease and Treatment 2009:5 35
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Ropinirole 24-hour
Ropinirole 24-hour has been compared to placebo in 
advanced PD in a 24-week study in subjects with suboptimal 
control with levodopa.24 At week 24, mean daily dose was 
18.8 mg/day. Mean reduction in off time was 2.1 hours with 
ropinirole compared with 0.3 with placebo. Quality of life 
indicators, depression and sleep scales were also improved. 
A direct comparison to ropinirole immediate release has 
also been done with a similar design. The odds of having a 
20% reduction in off time was signiﬁ  cantly higher in 24-hour 
compared to immediate release (64% versus 51%). Subjects 
were able to titrate to higher total daily doses, 18.6 mg versus 
10.4 mg, interpreted as better tolerability. Levodopa reduc-
tions were 162 mg/day versus 113 mg/day.
Safety and tolerability
Monotherapy with ropinirole 
immediate release
The most common report side effects across studies were 
nausea, dizziness and somnolence, typically ranging from 
10% to 20%.7,18–20 These side effects tend to peak during 
early titration and are diminished with longer term use, 
despite increase in dosing. Compared with levodopa, rop-
inirole produces more somnolence (27.4% versus 19.1%), 
hallucinations (17.3% versus 5.6%) and lower extremity 
edema (14.0% versus 5.6%).7 Nausea, dizziness and insom-
nia are similar between the two therapies. Sudden attacks 
of sleepiness resulting in motor vehicle accidents have been 
reported since approval,25 leading to a warning on the label. 
Additional label changes since approval include warnings 
concerning pathological gambling and other impulse control 
disorders (ICD).26 Recently, Weintraub et al summarized 
a prevalence study in which ICDs as a group were more 
common in patients treated with a dopamine agonist than 
non-dopamine agonist treated patients (17.1% versus 6.9%). 
There was no difference in ICD frequency with pramipexole 
(17.7%) versus ropinirole (15.5%). ICDs seen were compul-
sive buying (7.2%), gambling (6.4%), binge eating (5.6%) 
and compulsive sexual behavior (4.4%).26
Adjunctive therapy with ropinirole 
immediate release
As adjunctive therapy to levodopa, ropinirole has a similar side 
effect proﬁ  le as in monotherapy, with the exception of exacer-
bation of dyskinesia. Compared with placebo, dyskinesia are 
seen in 34% versus 13%.22 Compared with bromocriptine, dys-
kinesia was seen 26% versus 14%. However, in the long term 
efﬁ  cacy trials in early PD, dyskinesia in subjects started on 
ropinirole was less than those started on levodopa, suggesting 
that the levodopa sparing factor may be important in reducing 
overall levels of dyskinesia.7
Ropinirole 24-hour
Ropinirole 24-hour, not surprisingly, seems to have a similar 
adverse event profile as ropinirole immediate release. 
As adjunctive therapy, the most common side effects seen 
were dyskinesia (13%), nausea (11%), dizziness (8%) and 
somnolence (7%).24 This compares with placebo where these 
same side effects were 4%, 3% and 4% respectively. Pub-
lished data on comparison with immediate release ropinirole 
are somewhat lacking. A paper reviewing pharmacokinetics 
in small numbers of patients also discusses adverse effects 
and notes similar tolerability between ropinirole 24-hour and 
ropinirole immediate release with roughly the same total daily 
doses. A recent abstract suggests that ropinirole 24-hour can 
be titrated to higher daily doses in advanced PD27 suggesting 
better tolerability with a second abstract examining the same 
study supporting that conclusion.28 No long term data are 
available to assess the frequency of impulse control disorder; 
however, one would expect little difference compared with 
immediate release.
Patients can be safely switched overnight from immediate 
release to ropinirole 24-hour.17 With switching between dopa-
mine agonists, rapid titration is preferable to slow titration 
in advanced Parkinson’s disease.29
Patient view
In a Harris poll completed in 2003 (www.harrisinteractive.
com), 228 patients with PD diagnosed more than 5 years were 
asked to rate their disease. Seventy-ﬁ  ve percent reported at 
least 3 hours of off time per day. The average person took 
19 pills per day, of which 60% were for PD. PD medication 
were taken an average of 4.5 times per day. Sixty-eight 
percent sometimes forgot to take medication; 41% did so 
regularly. Minimal side effects, improvement in daily on time 
and once-daily dosing were rated as ﬁ  rst, third and seventh 
in terms of importance.
A survey of 250 PD patients on ropinirole immediate 
release showed that 67% of patients had missed doses (24%) 
or were late on a dose (57%) in the last week.30 Eighty-eight 
percent expressed interest in a once-daily formulation.
Conclusion
Ropinirole is regarded as a highly effective agent in treating 
the signs and symptoms of PD. While it is assumed the that Neuropsychiatric Disease and Treatment 2009:5 36
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the long acting compound (Requip® XL™) will offer similar 
efﬁ  cacy, the decreased pill burden and once daily therapy 
may improve patient compliance and as a result, provide 
additional symptomatic beneﬁ  t. Furthermore, the reduced 
number of peak dose effects may have an impact on the 
drowsiness and orthostatic hypotension, thus improving 
tolerability to the agent.
Disclosures
The authors have no conﬂ  icts of interest to disclose.
References
  1.  Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of 
ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol 
Biochem Behav. 1991;38:147–154.
 2. de Mey C, Enterling D, Meineke I, Yeulet S. Interactions between 
domperidone and ropinirole, a novel dopamine D2-receptor agonist. 
Br J Clin Pharmacol. 1991;32:483–488.
  3.  Eden RJ, Wallduck MS, Patel B, Owen DA. Autonomic and haemo-
dynamic responses to SK&F 101468 (ropinirole), a DA2 agonist, in 
anaesthetised cats. Eur J Pharmacol. 1990;175:333–340.
 4.  Parker SG, Raval P, Yeulet S, Eden RJ. Tolerance to peripheral, but 
not central, effects of ropinirole, a selective dopamine D2-like receptor 
agonist. Eur J Pharmacol. 1994;265:17–26.
 5.  Acton G, Broom C. A dose rising study of the safety and effects on 
serum prolactin of SK&F 101468, a novel dopamine D2-receptor 
agonist. Br J Clin Pharmacol. 1989;28:435–441.
  6.  Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. 
Dopamine D2 receptor-mediated antioxidant and neuroprotective effects 
of ropinirole, a dopamine agonist. Brain Res. 1999;838:51–59.
  7.  Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. 
A ﬁ  ve-year study of the incidence of dyskinesia in patients with early 
Parkinson’s disease who were treated with ropinirole or levodopa. 056 
Study Group. N Engl J Med. 2000;342:1484–1491.
 8. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of 
Parkinson’s disease with ropinirole versus levodopa: The REAL-PET 
study. Ann Neurol. 2003;54:93–101.
 9. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of 
Parkinson’s disease. Am J Health Syst Pharm. 1999;56:217–224.
 10.  Boothman BR, Spokes EG. Pharmacokinetic data for ropinirole. Lancet. 
1990;336:814.
  11. Swagzdis JE, Wittendorf RW, DeMarinis RM, Mico BA. Pharma-
cokinetics of dopamine-2 agonists in rats and dogs. J Pharm Sci. 
1986;75:925–928.
  12. Thalamas C, Taylor A, Brefel-Courbon C, Eagle S, Fitzpatrick K, 
Rascol O. Lack of pharmacokinetic interaction between ropinirole and 
theophylline in patients with Parkinson’s disease. Eur J Clin Pharmacol. 
1999;55:299–303.
  13. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin 
Pharmacokinet. 2000;39:243–254.
14. Brefel C, Thalamas C, Rayet S, et al. Effect of food on the 
pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin 
Pharmacol. 1998;45:412–415.
15.  Ramji JV, Keogh JP, Blake TJ, et al. Disposition of ropinirole in animals 
and man. Xenobiotica. 1999;29:311–325.
16.  Hubble J, Koller WC, Atchison P, et al. Linear pharmacokinetic behav-
ior of ropinirole during multiple dosing in patients with Parkinson’s 
disease. J Clin Pharmacol. 2000;40:641–646.
17. Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of 
a 24-hour prolonged-release formulation of ropinirole: results of two 
randomized studies in patients with Parkinson’s disease. Clin Ther. 
2007;29:2654–2666.
18.  Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of 
early Parkinson’s disease. The Ropinirole Study Group. Neurology. 
1997;49:393–399.
19. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evalua-
tion of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in 
Parkinson’s disease. Clin Neuropharmacol. 1998;21:101–107.
20.  Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. 
Ropinirole versus bromocriptine in the treatment of early Parkinson’s 
disease: a 6-month interim report of a 3-year study. 053 Study Group. 
Mov Disord. 1998;13:46–51.
21.  Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of 
Parkinson’s disease patients randomized to initial therapy with 
ropinirole or levodopa. Mov Disord. 2007;22:2409–2417.
22. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of 
ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole 
Study Group. Neurology. 1998;51:1057–1062.
23.  Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa 
in the treatment of Parkinson’s disease: a 16-week bromocriptine 
controlled study. J Neurol. 2003;250:90–96.
24.  Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged 
release: randomized, controlled study in advanced Parkinson disease. 
Neurology. 2007;68:1108–1115.
25.  Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep 
at the wheel: motor vehicle mishaps in persons taking pramipexole and 
ropinirole. Neurology. 1999;52:1908–1910.
26.  Weintraub A, Koester J, Potenza MN, et al. Dopaminergic therapy and 
impulse control disorders in Parkinson’s disease: Top line results of a 
cross sectional study of over 3,000 patients. In: Movement Disorder 
Society’s 12th International Congress of Parkinson’s disease and 
Movement Disorders. Chicago, Il; 2008.
27. Schapira AHV, Stocchi F, Hunter B, Giorgi L. Comparison of adjunctive 
ropinirole 24-hour prolonged release and immediate release in patietns 
with advanced Parkinson’s disease: A per-protocol analysis ofthe 
PREPARED study. Mov Disord. 2008;23:S196–197.
28.  Stocchi F, Tompson DJ, Giorgi L. Dosing of ropinirole 24-hour 
prolonged release in Parkinson’s disease: Clinical trial data and 
relevance to clinical practice. Mov Disord. 2008;23:S214.
29.  Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in 
advanced Parkinson’s disease: is rapid titration preferable to slow? 
Neurology. 1999;52:1227–1229.
30.  Edin HM, DeBenedetti DB, Hill CD. Adherence among Parkinson’s 
disease patietns taking ropinirole immediate release at least thrice daily. 
Mov Disord. 2008;23:S344–345.